Cantor Fitzgerald Predicts Tourmaline Bio FY2026 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Tourmaline Bio in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($2.91) per share for the year. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share.

TRML has been the subject of a number of other research reports. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Tourmaline Bio in a research report on Monday, May 5th. Wedbush boosted their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. Lifesci Capital initiated coverage on shares of Tourmaline Bio in a research note on Monday, February 24th. They set an "outperform" rating and a $58.00 target price on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tourmaline Bio has a consensus rating of "Buy" and a consensus target price of $49.33.

Tourmaline Bio Price Performance

Shares of NASDAQ:TRML traded down $0.22 on Wednesday, reaching $19.68. 154,595 shares of the company traded hands, compared to its average volume of 275,218. Tourmaline Bio has a fifty-two week low of $11.56 and a fifty-two week high of $29.79. The company's 50 day moving average is $16.23 and its 200-day moving average is $17.17. The stock has a market capitalization of $505.48 million, a PE ratio of -6.98 and a beta of 2.05.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

Hedge Funds Weigh In On Tourmaline Bio

Hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in shares of Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after acquiring an additional 1,232 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Tourmaline Bio in the fourth quarter worth $47,000. Brooklyn Investment Group increased its stake in shares of Tourmaline Bio by 148.9% in the first quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock worth $60,000 after acquiring an additional 2,347 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in shares of Tourmaline Bio in the fourth quarter worth $64,000. Finally, GAMMA Investing LLC boosted its holdings in Tourmaline Bio by 4,481.7% in the first quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock worth $114,000 after purchasing an additional 7,350 shares in the last quarter. 91.89% of the stock is owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.